Celgene cancer drug acquisition may bode well for life science M&A

Celgene (NYSE:CELG) has acquired cancer drug developer Avila Therapeutics in a deal valued up to $925 million if milestones are reached. Avila’s therapeutic platform involves the development of covalent drugs, which¬† latch onto or bond with target cells and effectively neutralize those cells. Avila’s lead therapeutic, AVL-292, is a lymphoma and autoimmune drug in phase […]